nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

09.05.2018 | Letter to the Editor

Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration—the future has begun

verfasst von: Justus G. Garweg, J. J. Zirpel, C. Gerhardt, Isabel B. Pfister

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Garweg JG, Zirpel JJ, Gerhardt C, Pfister IB (2018) The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol 256:823–831CrossRef

Ip MS, Zhang J, Ehrlich JS (2017) The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology 124:596–603CrossRef

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRef

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRef

Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627–637CrossRef

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731–1739CrossRef

Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628CrossRef

Quaggin SE (2012) Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122:3849–3851CrossRef

Garweg JG (2016) Makula-Atrophie bei feuchter altersabhängiger Makula- Degeneration – unausweichliche Folge der anti-VEGF-Therapie ? Ophthalmologe 113:1036–1045CrossRef

10.

Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists’ Guidelines Committee (EURETINA) (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486–494CrossRef

11.

Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, Sustain Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663–671CrossRef

12.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:1751–1761CrossRef

13.

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299CrossRef

14.

Garweg JG, Niderprim SA, Russ HM, Pfister IB (2017) Comparison of strategies of treatment with ranibizumab in newly-diagnosed cases of Neovascular age-related macular degeneration. J Ocul Pharmacol Ther 33:773–778CrossRef

15.

Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, European Society of Retina Specialists (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144–1167CrossRef

16.

Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunović H (2017) A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond). 31:26–44CrossRef

17.

Lanzetta P, Loewenstein A, Vision Academy Steering Committee (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 255:1259–1273CrossRef

18.

Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 29:721–731CrossRef

19.

Garweg JG, Russ HM, Pfister IB (2017) Early response to ranibizumab is predictive of treatment demand after a therapeutic switch to aflibercept. Ophthalmology Retina 1:210–216CrossRef

20.

Stewart MW (2015) Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? Or losing? J Clin Med. 4:1079–1101CrossRef

21.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR, TREX-AMD Study Group (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRef

22.

Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR, TREX-AMD Study Group (2018) Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol 102:460–464CrossRef

23.

Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2016) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100:914–917 Though our study suggests superiority of the treat and extend regimen to PRN treatment in a 12-month period, this review demonstrates the need for randomised clinical trials to confirm our findings and to evaluate long-term efficacy outcomes with these regimens compared with monthly therapyCrossRef

24.

Schlottmann PG, Alezzandrini AA, Zas M, Rodriguez FJ, Luna JD, Wu L (2017) New treatment modalities for Neovascular age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 6:514–519

25.

Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, Barthelmes D, Gillies MC (2018) Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res pii S1350-9462(17):30105–30102

26.

Ord LM, Wright J, DeAngelis MM, Feehan M (2016) Quality of life with macular degeneration is not as dark as it may seem: patients’ perceptions of the MacDQoL questionnaire. J Clin Med 4:1841–1852CrossRef

27.

Cascella R, Strafella C, Caputo V, Errichiello V, Zampatti S, Milano F, Potenza S, Mauriello S, Novelli G, Ricci F, Cusumano A, Giardina E (2018) Towards the application of precision medicine in age-related macular degeneration. Prog Retin Eye Res 63:132–146CrossRef

28.

Wei X, Zhang T, Yao Y, Zeng S, Li M, Xiang H, Zhao C, Cao G, Li M, Wan R, Yang P, Yang J (2018) Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Exp Eye Res 168:2–11CrossRef

Titel: Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration—the future has begun
verfasst von: Justus G. Garweg
J. J. Zirpel
C. Gerhardt
Isabel B. Pfister
Publikationsdatum: 09.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 8/2018
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-4005-x

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration—the future has begun

Excerpt

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

The role of the vitreous body in effective IOL positioning

Optical coherence tomography angiography in pachychoroid spectrum diseases

Vessel density, retinal thickness, and choriocapillaris vascular flow in myopic eyes on OCT angiography

Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy

Fixation behavior in macular dystrophy assessed by microperimetry

OCTA vessel density changes in the macular zone in glaucomatous eyes

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde